Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
100

Summary

Conditions
  • Diffuse Intrinsic Pontine Glioma
  • Ewing Sarcoma
  • Medulloblastoma
  • Neuroblastoma
  • Rhabdoid Tumor
  • Rhabdomyosarcoma
  • Solid Tumors
Type
Interventional
Phase
Phase 1
Design
Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: The palbociclib plus irinotecan and temozolomide combination part of the study will comprise of a dose escalation cohort (following a rolling 6 design), a dose expansion cohort, EWS tumor specific cohort and if applicable, other solid tumor-specific cohorts. The palbociclib plus topotecan and cyclophosphamide will comprise of a dose determination cohort(following a modified rolling 6 design), a dose expansion cohort, and if applicable, other solid tumor-specific cohorts.Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 2 years and 20 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT03709680
Collaborators
Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer